NEW YORK (GenomeWeb) – Globavir today announced a partnership with BioManguinhos, a division of the Oswaldo Cruz Foundation (Fiocruz), to evaluate the firm's PanGlob RT-PCR Dengue diagnostic assay.
Under the terms of the agreement, the partners will work together to evaluate and develop Globavir's PanGlob for commercial launch in Brazil.
Globavir said that the test is more sensitive in detecting Dengue virus from patient samples than other diagnostic assays and can detect it regardless of the virus' specific serotype.
"Through this partnership with BioManguinhos, Globavir's powerful diagnostic assay will be in position for deployment during the next Dengue season," Globavir President and CEO Shalabh Gupta said in a statement.
The firm said it is currently developing a point-of-care version of the test.
Los Altos, Calif.-based Globavir develops diagnostics and treatments for infectious diseases. BioManguinhos is the scientific technology unit of Fiocruz, a division of the Brazilian Ministry of Health.
The collaboration may result in future joint ventures or technology transfers, the partners said in a statement.
Financial and other details of the agreement were not disclosed.